Thursday, 21 November 2024

Viking Therapeutics is more than just a weight-loss stock, and that’s drawing cheers

by BD Banks

The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.
signup-banner